GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Sangamo Therapeutics
Sangamo Therapeutics is a pioneering company in the field of genome editing. Its stock price is a story of high hopes and mixed results. The chart reflects high volatility and dependence on news about clinical trials of its gene and cell therapies.
Share prices of companies in the market segment - Dna
Sangamo Therapeutics is a biotechnology company specializing in gene therapy, genome editing, and cell therapy for the treatment of genetic diseases. We classify it as a "DNA technology" company because it operates at the cutting edge of science. The chart below shows the dynamics of this disruptive, yet high-risk, sector.
Broad Market Index - GURU.Markets
Sangamo Therapeutics is a pioneer in genome editing, developing gene and cell therapies to treat rare diseases. As a component of the GURU.Markets index, it is at the forefront of science. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SGMO - Daily change in the company's share price Sangamo Therapeutics
Shares of Sangamo, a gene therapy company, exhibit high volatility, as measured by change_co. This indicator reflects sensitivity to clinical trial results. This metric is a key component of formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Dna
Sangamo Therapeutics, Inc. is a pioneer in gene therapy. This chart highlights the extreme volatility of the biotech sector. Comparison with SGMO's performance, which is dependent on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Sangamo Therapeutics is a pioneer in genomic medicine, developing treatments based on DNA editing. The company's shares are a bet on scientific revolution. Their extreme data-driven volatility is part of the dynamic of the innovative sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Sangamo Therapeutics
The year-over-year performance of Sangamo Therapeutics, a pioneer in gene editing, is a story of the search for clinical success. Its 12-month market cap is entirely dependent on the data from its gene therapy trials. Investors' long-standing expectations require fundamental confirmation that its cutting-edge science can be translated into real-world treatments.
Annual dynamics of market capitalization of the market segment - Dna
Sangamo Therapeutics, Inc. is a pioneering company in gene therapy. Its platform enables gene editing and regulation of gene expression. Its stock price is highly volatile, reflecting investor confidence in its long-term potential rather than current profitability, which is typical for the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sangamo, a pioneer in genome editing, is a bet on the technology of the future. Its stock price is completely unrelated to the economy. Its chart reflects the hopes, risks, and scientific breakthroughs in one of the most advanced fields of medicine. It's a long-term bet on a technology that could change the world.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Sangamo Therapeutics
Sangamo Therapeutics is at the forefront of genomic medicine, developing gene and cell therapies. Because its products are in the research stage, monthly price fluctuations reflect investor expectations. Clinical trial data and partnership news are the main drivers of the ups and downs on this chart.
Monthly dynamics of market capitalization of the market segment - Dna
This chart reflects the dynamics of the cutting-edge yet volatile gene therapy sector. For Sangamo, one of the pioneers, it's the backdrop. Its movements illustrate how successes and failures in clinical trials, as well as partnerships with major pharma companies, influence investor sentiment across the industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sangamo Therapeutics is a pioneer in genome editing and gene therapy, a revolutionary but highly risky area of biotechnology. The broader market has little impact on Sangamo; its shares are driven by news of clinical trials, and a single success or failure can trigger sharp movements, ignoring any macroeconomic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in gene editing and cell therapy. Its weekly stock price is volatile and depends on news about clinical trials of its therapeutic candidates for various genetic diseases.
Weekly dynamics of market capitalization of the market segment - Dna
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. Its stock reflects investor hopes for future medical breakthroughs. Compare its weekly performance to the pharmaceutical sector to see how its advanced yet risky technologies create a unique investment profile.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Sangamo is a pioneer in the field of genome editing. The company's shares are a pure bet on a technological revolution in medicine. A chart will show their extreme volatility and complete disconnect from market trends, as they are driven by scientific news.
Market capitalization of the company, segment and market as a whole
SGMO - Market capitalization of the company Sangamo Therapeutics
The market capitalization of Sangamo Therapeutics, a pioneer in gene therapy, is a story of great promise and challenges. Its volatile price reflects both the enormous potential of its technology and the disappointments of clinical trials. The current valuation is the market's attempt to value its scientific platform after a series of setbacks.
SGMO - Share of the company's market capitalization Sangamo Therapeutics within the market segment - Dna
Sangamo Therapeutics is a pioneer in genome editing and cell therapy. Its market share reflects its long history of research and the potential of its platform. The chart tells a complex story of great scientific promise, clinical setbacks, and the constant search for a breakthrough.
Market capitalization of the market segment - Dna
The chart below shows the overall value of the biotech sector. Sangamo Therapeutics is a pioneer in genome editing and cell therapy. The dynamics of this market are promising. Sangamo's story is a long and complex journey from fundamental science to the development of real drugs, requiring enormous investment and patience.
Market capitalization of all companies included in a broad market index - GURU.Markets
Sangamo Therapeutics is a pioneer in the field of genome editing and gene therapy. Its market capitalization reflects its long history of research and the potential of its scientific platform. The chart below shows the economic weight of companies at the forefront of genetic engineering.
Book value capitalization of the company, segment and market as a whole
SGMO - Book value capitalization of the company Sangamo Therapeutics
Sangamo's foundation is its cutting-edge scientific platform for gene therapy and genome engineering. Its book value represents the capital it uses to conduct clinical trials. The graph tells the story of one of the pioneers in this field, which has been investing in its unique technology for decades, building a deep, yet uncommercialized, intangible asset.
SGMO - Share of the company's book capitalization Sangamo Therapeutics within the market segment - Dna
Sangamo Therapeutics is a pioneer in gene therapy and genome editing. The chart shows its share of actual R&D and manufacturing assets. These include its laboratories and plant where drugs capable of correcting genetic defects are developed and manufactured.
Market segment balance sheet capitalization - Dna
Sangamo Therapeutics is a pioneer in gene editing. Its value lies in its patents and scientific discoveries, not its manufacturing plants. The chart below reflects the enormous capital intensity of the pharmaceutical sector, demonstrating how lightweight its business model is.
Book value of all companies included in the broad market index - GURU.Markets
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. The company's assets include its unique scientific platform. A small stake in BCap_All provides the foundation for technologies that could offer a one-time treatment for previously incurable genetic diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in genetic engineering. Its valuation has fallen below book value after a series of clinical trial failures. The chart shows how the market is losing faith in its scientific platform.
Market to book capitalization ratio in a market segment - Dna
Sangamo Therapeutics is a pioneer in gene editing and cell therapy. Its valuation is based on its scientific platform. The chart shows the premium investors are paying for its decades of experience and broad pipeline, despite the lack of major commercial successes.
Market to book capitalization ratio for the market as a whole
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. Its value lies in its scientific platform and long history of development. This chart shows how the market values biotech veterans whose technologies may finally find widespread application, and the premium it places on this potential.
Debts of the company, segment and market as a whole
SGMO - Company debts Sangamo Therapeutics
Sangamo Therapeutics, a pioneer in gene therapy and genome editing, funds its cutting-edge research with borrowed capital. Its debt burden reflects the enormous costs of conducting clinical trials for its complex therapeutic approaches, which could lead to treatments for previously untreatable genetic diseases.
Market segment debts - Dna
Sangamo Therapeutics is a pioneer in gene therapy and genome editing, one of the most cutting-edge and capital-intensive fields of science. Due to the high risks, it is almost exclusively funded through equity. This chart shows how the company finances its breakthrough, yet extremely expensive, research at the forefront of medicine.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in genome editing and gene therapy, a cutting-edge but extremely expensive field of science. This chart shows how reliant the company is on debt to fund its breakthrough but high-risk research. This is a key indicator of its financial health and ability to continue operating.
Market segment debt to market segment book capitalization - Dna
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. This chart shows debt trends in the biotech sector. For a company working with cutting-edge technologies like zinc fingers, this allows them to assess how they finance their long-term, capital-intensive research and how their financial model compares to their peers.
Debt to book value of all companies in the market
Sangamo Therapeutics is a pioneer in gene therapy and genome editing. For decades, the company has been at the forefront of science, requiring massive shareholder-funded investments. This chart of the market's total debt burden clearly illustrates the gap between Sangamo's financial model and the traditional economy. Its value lies in its intellectual property, not its ability to service debt.
P/E of the company, segment and market as a whole
P/E - Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in gene therapy and genome editing. This chart shows that the company's valuation is based on the long-term potential of its scientific platform. Investors are betting that its technologies will treat previously untreatable genetic diseases, ignoring its current lack of profitability.
P/E of the market segment - Dna
This chart shows the average valuation for biotech companies, providing context for Sangamo Therapeutics. It reflects generally high valuations based on hopes for a breakthrough. Comparisons with this chart help understand how the market views Sangamo's long-standing efforts in genome editing and cell therapy and whether it believes it can bring its technologies to commercial success.
P/E of the market as a whole
Sangamo Therapeutics is a pioneer in the field of genome editing and gene therapy. The company operates at the cutting edge of science. Its valuation is based on the potential of its technology platform. This chart of overall biotech risk appetite shows whether investors are willing to continue funding Sangamo, despite its long journey from lab to market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in genomic medicine, developing therapies based on gene editing and gene regulation. This graph reflects speculative expectations for its cutting-edge technologies. The valuation depends on the long-term potential of its scientific platform and the results of clinical trials in areas such as rare genetic and neurological diseases.
%20P%2FE%20Sangamo%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Sangamo-Therapeutics&v=1772676286191 "Chart of the company's future (projected) P/E Sangamo Therapeutics")
Future (projected) P/E of the market segment - Dna
Sangamo Therapeutics is a pioneer in genome editing, developing therapeutics based on zinc finger technology. This chart reflects investor expectations for the company's profitability relative to the sector. It provides an insight into the market's confidence in its scientific platform and its application to the treatment of genetic diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772676286207 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. For a company operating at the cutting edge of science, this market risk appetite curve is vital. Funding for their breakthrough, yet highly capital-intensive, research directly depends on investors' willingness to invest in long-term, high-risk biotech projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772676286222 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in the field of genome editing and gene therapy. The company develops treatments for genetic diseases. This chart shows the financial health of a company operating at the cutting edge of science, where research costs are high and success is not guaranteed.
Profit of companies in the market segment - Dna
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. This chart shows the profitability of the DNA technology sector. For SGMO, it reflects both the hopes and challenges of this cutting-edge field of science. Their decades of experience developing zinc fingers gives them a unique platform for developing new treatments.
Overall market profit
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. The company develops treatments for genetic diseases. This is cutting-edge science with enormous potential, but also high risks. The company's valuation is based on its technology platform. General economic cycles, as reflected in this chart, do not affect its scientific activities.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. The profit projections presented here are speculative and reflect expectations of the success of its zinc-finger-based platform in clinical trials for the treatment of various genetic diseases. This represents a high-risk bet on breakthrough science.
%20profit%20of%20the%20company%20Sangamo%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Sangamo-Therapeutics&v=1772676286421 "Graph of future (projected) profit of the company Sangamo Therapeutics")
Future (predicted) profit of companies in the market segment - Dna
Sangamo Therapeutics is a pioneer in the field of genome editing and gene therapy. The profit forecast for this cutting-edge sector depends on the clinical success and commercialization of this revolutionary technology. This chart reflects analysts' long-term belief that genetic engineering will offer cures for many previously incurable diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772676286457 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. The company develops treatments for genetic diseases. The market profit forecasts shown here reflect the overall investor appetite for risk, which is necessary to fund revolutionary, yet very long-term, scientific research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772676286482 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. This chart shows the speculative valuation of the company, which has been in the research stage for many years. Investors value the potential of its scientific platform for developing drugs for rare genetic diseases, despite the lack of commercial products.
P/S market segment - Dna
Sangamo Therapeutics is a pioneer in genomic medicine, developing treatments based on genome editing and gene therapy for various diseases. This is one of the most advanced fields of science. This chart shows the average revenue estimate in the biotech sector, which helps us understand the premium the market is paying for Sangamo's breakthrough scientific platform.
P/S of the market as a whole
Sangamo Therapeutics is a pioneer in genome editing, developing gene and cell therapies to treat genetic diseases. The company is in clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in genome editing and gene therapy, developing treatments for genetic diseases. This chart shows how the market values the company based on its future revenue potential. It reflects the high expectations for its scientific platform.
%20P%2FS%20Sangamo%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Sangamo-Therapeutics&v=1772676286684 "The graph of the company's future (projected) P/S Sangamo Therapeutics")
Future (projected) P/S of the market segment - Dna
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. The company is developing treatments for a wide range of genetic diseases. This chart reflects the market's assessment of its cutting-edge scientific platform and the long-term potential of its technologies to revolutionize medicine.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772676286717 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Sangamo Therapeutics is a pioneer in gene editing and gene therapy, a high-tech and risky field. This market optimism is vital for SGMO. Raising massive funds for such breakthrough, yet long-term, research is only possible with a high investor appetite for risk and faith in scientific progress.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772676286749 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Sangamo Therapeutics
Sangamo Therapeutics is a pioneering company in gene therapy and genome editing. Despite its long history, the company is still in the clinical stage. This chart shows that its revenue is minimal and comes primarily from partnerships. Future growth depends on whether it can finally bring its first commercial product to market.
Sales of companies in the market segment - Dna
Sangamo Therapeutics is a pioneer in genomic medicine. They develop cutting-edge treatments based on gene editing, gene therapy, and cell therapy for rare genetic diseases. Their revenue currently comes primarily from partnerships with major pharmaceutical companies.
Overall market sales
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. The company develops treatments for genetic diseases by correcting or modifying DNA. This revenue chart includes the innovative healthcare sector, where SGMO works with cutting-edge technologies that have the potential to revolutionize medicine.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Sangamo Therapeutics
Sangamo Therapeutics is one of the oldest gene therapy companies, specializing in zinc-finger technology for genome editing. This chart reflects analysts' confidence in its scientific platform and ability to commercialize complex treatments.
%20sales%20of%20the%20company%20Sangamo%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Sangamo-Therapeutics&v=1772676286893 "Schedule of future (projected) sales of the company Sangamo Therapeutics")
Future (projected) sales of companies in the market segment - Dna
Sangamo Therapeutics is a pioneer in genetic engineering, developing treatments based on genome editing and gene therapy technologies. This chart shows forecasts for the advanced gene medicine market. It reflects the enormous expectations for the development of technologies that can treat genetic diseases, not just their symptoms.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772676286954 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Sangamo Therapeutics, a pioneer in genome editing, sees this chart as a reflection of long-term investments in breakthrough technologies. The stable economic growth predicted here allows investors and pharmaceutical companies to fund fundamental research in gene therapy, which is critical for the development of next-generation drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772676286984 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. While in clinical development, the company incurs significant research expenses. This chart does not represent current revenue, but rather the investment in its cutting-edge scientific platform, which represents the cost of developing potentially revolutionary treatments.
Market segment marginality - Dna
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. This graph reflects the potential of its scientific platform. Future high operating income will confirm that its technologies can form the basis of a new generation of drugs for genetic diseases.
Market marginality as a whole
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. It is a clinical-stage company whose value is based on the potential of its scientific platform. This gross profitability chart bears no relation to the world of advanced biotechnology, where risks and opportunities are determined by science.
Employees in the company, segment and market as a whole
Number of employees in the company Sangamo Therapeutics
Sangamo Therapeutics is a pioneer in the field of genome editing. The company develops gene and cell therapies based on its zinc finger technology. This graphic shows a team of scientists working on developing potentially curative treatments for a wide range of genetic diseases.
Share of the company's employees Sangamo Therapeutics within the market segment - Dna
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. Developing such breakthrough zinc-finger-based technologies requires a world-class team of scientists. This chart shows the concentration of elite scientific talent, reflecting the company's standing at the forefront of genetic medicine.
Number of employees in the market segment - Dna
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. The company develops treatments for rare genetic diseases and cancer. This graphic shows an elite team of genetic scientists working at the cutting edge of science, attempting to correct the genetic errors that underlie many serious diseases.
Number of employees in the market as a whole
Sangamo Therapeutics is a pioneer in genomic medicine, developing treatments based on gene editing and cell therapy. Their cutting-edge research requires significant investment. The overall economic climate, as measured by employment trends, creates conditions for attracting the capital needed to advance these revolutionary treatments into the clinic.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Sangamo Therapeutics (SGMO)
Sangamo Therapeutics is a pioneer in gene therapy and genome editing. This chart represents their revolutionary scientific platform. Their astronomically high market cap per employee reflects the market's belief that their technology can lead to cures for numerous previously incurable diseases. This represents enormous potential.
%20of%20the%20company%20Sangamo%20Therapeutics%20(SGMO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Sangamo-Therapeutics-SGMO&v=1772676287335 "Chart of market capitalization per employee (in thousands of dollars) of the company Sangamo Therapeutics (SGMO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Sangamo Therapeutics is a pioneer in genomic medicine, developing gene-editing treatments. Its value lies in its cutting-edge scientific platform and intellectual property. This chart shows how highly the market values its technological breakthrough per research team compared to other biotech companies.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772676287367 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. In this cutting-edge field, this metric reflects the immense value of its technologies. Its high market capitalization per employee reflects investors' appreciation of the potential of its platforms for developing treatments for a wide range of genetic diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772676287377 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Sangamo Therapeutics (SGMO)
Sangamo Therapeutics is a pioneer in genome editing (zinc finger technology). It's a clinical-stage biotech company. This graph is negative. The company has spent hundreds of millions on R&D for decades. Its entire staff consists of scientists working on developing breakthrough gene therapies.
%20Chart%20Sangamo%20Therapeutics%20(SGMO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Sangamo-Therapeutics-SGMO&v=1772676287394 "Company Profit Per Employee (in thousands of dollars) Chart Sangamo Therapeutics (SGMO)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Sangamo Therapeutics is a pioneer in genetic engineering, specializing in zinc-finger nanotechnology (ZFN) for genome editing and cell therapy. This chart represents an industry benchmark. For biotech R&D companies working at the forefront of science, it serves as a benchmark, demonstrating the potential profitability the sector aspires to if their unique technology platform is successful.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772676287397 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Sangamo Therapeutics is one of the oldest gene therapy companies, specializing in zinc-finger genes (ZFNs) for genome editing. It has extensive R&D. The chart shows the R&D investment (negative return) per scientist working on this complex technology platform, which has not yet produced commercial products.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772676287426 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Sangamo Therapeutics (SGMO)
Sangamo Therapeutics is a pioneer in genome editing and gene therapy. This graph reflects the long journey from scientific discovery to drug development. The company's potentially enormous revenue per employee in the future will come from the successful application of its technologies to treat genetic diseases, which could lead to a breakthrough in medicine.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Sangamo-Therapeutics-SGMO&v=1772676287428 "Sales chart per company employee Sangamo Therapeutics (SGMO)")
Sales per employee in the market segment - Dna
Sangamo Therapeutics (SGMO) is a pioneer in the field of genome editing (zinc fingers) and cell therapy. They are a clinical-stage R&D company with no stable revenue. This chart reflects their R&D stage: their research staff is focused on research, resulting in low revenue per employee compared to the industry average.
Sales per employee for the market as a whole
Sangamo is a pioneer in gene editing (zinc finger technology). They are developing gene therapies for rare diseases. This is a pure R&D business. This graph will likely show minimal revenue (from partnerships), as their team of scientists has not yet developed commercial products.
Short shares by company, segment and market as a whole
Shares shorted by company Sangamo Therapeutics (SGMO)
Sangamo (SGMO) is one of the oldest gene therapy companies, specializing in gene editing using zinc-finger gene-editing technology (ZFN). This chart measures bearish bets. The high short interest in SGMO reflects investor frustration with years of clinical trial failures and the belief that their ZFN technology has lost the race to the newer, simpler CRISPR.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Sangamo-Therapeutics-SGMO&v=1772676287456 "Short Shares Chart for the Company Sangamo Therapeutics (SGMO)")
Shares shorted by market segment - Dna
Sangamo (SGMO) is a pioneer in genome editing, developing gene and cell therapies based on zinc finger technology. This chart illustrates the general skepticism in the genetic engineering sector. It reflects the enormous risks and investor doubts about the success of clinical trials in this complex field.
Shares shorted by the overall market
Sangamo (SGMO) is a gene therapy pioneer with decades of R&D experience. It's a classic "hope stock." When this fear indicator rises, investors run out of patience. They sell off unprofitable "research projects" like SGMO en masse, preferring companies with real profits.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Sangamo Therapeutics (SGMO)
Sangamo Therapeutics is a pioneer in gene therapy that has experienced numerous R&D setbacks. The company is betting on "zinc finger" technology. This chart measures fading hope. It shows when the stock is "oversold" due to despair or "overbought" due to rare speculative news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Sangamo-Therapeutics-SGMO&v=1772676287507 "RSI 14 indicator chart for the company's stock Sangamo Therapeutics (SGMO)")
RSI 14 Market Segment - Dna
Sangamo Therapeutics is a pioneer in the field of genetic engineering. They specialize in developing genomic drugs using zinc-finger DNA editing technology (ZFN). This chart reflects the general sentiment in the genetic engineering sector and helps assess how overheated this futuristic biotech segment is.
RSI 14 for the overall market
Sangamo (SGMO), a company engaged in "genome editing," is on the rise. This graph is its lifeline. Its business is pure R&D. During periods of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and SGMO risks running out of funds for its research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SGMO (Sangamo Therapeutics)
Sangamo (SGMO) is a pioneer in genome editing, specializing in zinc-finger gene therapy (ZFN) technology. This chart shows the average target price. It reflects analysts' speculative valuation of this technology and its ability to compete with CRISPR in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SGMO-Sangamo-Therapeutics&v=1772676287550 "A chart showing analyst consensus forecasts for the expected stock price. SGMO (Sangamo Therapeutics)")
The difference between the consensus estimate and the actual stock price SGMO (Sangamo Therapeutics)
Sangamo Therapeutics is a pioneer in genome editing using zinc-finger technology (ZFN). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief that this technology will finally deliver clinical results.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SGMO-Sangamo-Therapeutics&v=1772676287551 "A chart showing the difference between the consensus forecast and the actual stock price. SGMO (Sangamo Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Dna
Sangamo Therapeutics is a pioneer in gene editing, developing zinc finger (ZFN) peptides—an alternative to CRISPR for treating genetic diseases. This chart shows analysts' overall expectations for the DNA technology sector. It reflects whether experts believe in this technology or think CRISPR has won.
Analysts' consensus forecast for the overall market share price
Sangamo Therapeutics is a pioneer in gene therapy, specializing in zinc-finger gene therapy (ZFN), a genome-editing technology that competes with CRISPR. This chart shows overall market sentiment. For Sangamo, a scientific R&D company, it's important to understand how risk appetite (sentiment) influences funding for their long-term and complex programs. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Sangamo Therapeutics
Sangamo Therapeutics is a veteran of genetic engineering. They are pioneers of zinc-finger genome editing (ZFN), which they use to treat rare genetic diseases. This chart is a clear indicator of faith in their science. It reflects the market's assessment of their (very long) R&D progress and their ability to compete with new technologies like CRISPR.
AKIMA Market Segment Index - Dna
Sangamo Therapeutics is a pioneer in genome editing, specializing in zinc finger technology (ZFN) for the development of gene and cell therapies. This chart shows the average index for the DNA technologies segment. It allows investors to assess how Sangamo, with its unique technology platform, outperforms or underperforms the sector average.
The AKIM Index for the overall market
Sangamo Therapeutics is a pioneer in the field of genome editing (zinc fingers). It develops genomic drugs for neurological diseases. This chart, reflecting the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this veteran scientific platform undergoing restructuring.
